Fungus-Specific CD4 T Cells as Specific Sensors for Identification of Pulmonary Fungal Infections

Mycopathologia

Volumn 183, Issue 1, 2018, Pages 213-226

  Scheffold, Alexander ^a,b   Schwarz, Carsten ^a   Bacher, Petra ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b POTSDAM INSTITUTE FOR CLIMATE IMPACT RESEARCH PIK   (Germany)

Author keywords

ABPA; ARTE; Cystic fibrosis; Fungal infection; Fungal pathogen; T cell

Indexed keywords

CD4+ T LYMPHOCYTE; COMPLICATION; CYSTIC FIBROSIS; FUNGUS; HUMAN; IMMUNOASSAY; IMMUNOLOGY; LABORATORY TECHNIQUE; LUNG MYCOSIS; PROCEDURES;

CD4-POSITIVE T-LYMPHOCYTES; CLINICAL LABORATORY TECHNIQUES; CYSTIC FIBROSIS; FUNGI; HUMANS; IMMUNOASSAY; LUNG DISEASES, FUNGAL;

EID: 85034663583     PISSN: 0301486X     EISSN: 15730832     Source Type: Journal    
DOI: 10.1007/s11046-017-0229-2     Document Type: Article

References (136)

1. Emerson J, Rosenfeld M, McNamara S, et al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 2002;34:91–100.
2. Rosenfeld M, Gibson RL, McNamara S, et al. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol. 2001;32:356–66.
3. Delhaes L, Monchy S, Frealle E, et al. The airway microbiota in cystic fibrosis: a complex fungal and bacterial community–implications for therapeutic management. PLoS ONE. 2012;7:e36313.
4. Pihet M, Carrere J, Cimon B, et al. Occurrence and relevance of filamentous fungi in respiratory secretions of patients with cystic fibrosis–a review. Med Mycol. 2009;47:387–97.
5. Schwarz C, Brandt C, Antweiler E, et al. Prospective multicenter German study on pulmonary colonization with Scedosporium/Lomentospora species in cystic fibrosis: epidemiology and new association factors. PLoS ONE. 2017;12:e0171485.
6. Sudfeld CR, Dasenbrook EC, Merz WG, et al. Prevalence and risk factors for recovery of filamentous fungi in individuals with cystic fibrosis. J Cyst Fibros. 2010;9:110–6.
7. Whittaker LA, Teneback C. Atypical mycobacterial and fungal infections in cystic fibrosis. Semin Respir Crit Care Med. 2009;30:539–46.
8. Giraud S, Pihet M, Razafimandimby B, et al. Geosmithia argillacea: an emerging pathogen in patients with cystic fibrosis. J Clin Microbiol. 2010;48:2381–6.
9. Matos T, Cerar T, Praprotnik M, et al. First recovery of Rasamsonia argillacea species complex isolated in adolescent patient with cystic fibrosis in Slovenia–case report and review of literature. Mycoses. 2015;58:506–10.
10. Ziesing S, Suerbaum S, Sedlacek L. Fungal epidemiology and diversity in cystic fibrosis patients over a 5-year period in a national reference center. Med Mycol. 2016;54:781–6.
11. What is allergic bronchopulmonary aspergillosis. (ABPA)? Am J Respir Crit Care Med. 2014;190:P3–4.
12. Antunes J, Fernandes A, Borrego LM, et al. Cystic fibrosis, atopy, asthma and ABPA. Allergol Immunopathol (Madr). 2010;38:278–84.
13. Hartl D. Immunological mechanisms behind the cystic fibrosis-ABPA link. Med Mycol. 2009;47(Suppl 1):S183–91.
14. Jubin V, Ranque S, Stremler Le Bel N, et al. Risk factors for Aspergillus colonization and allergic bronchopulmonary aspergillosis in children with cystic fibrosis. Pediatr Pulmonol. 2010;45:764–71.
15. Mastella G, Rainisio M, Harms HK, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis. A European epidemiological study. Eur Respir J. 2000;16:464–71.
16. Maturu VN, Agarwal R. Prevalence of Aspergillus sensitization and allergic bronchopulmonary aspergillosis in cystic fibrosis: systematic review and meta-analysis. Clin Exp Allergy. 2015;45:1765–78.
17. Milla CE. Allergic bronchopulmonary aspergillosis and cystic fibrosis. Pediatr Pulmonol. 1999;27:71–3.
18. Schwarz CTA, Staab D, Tintelnot K. Scedosporium apiospermum: a fungal pathogen causing pneumonia in a patient with cystic fibrosis. JMM Case Rep. 2015;. https://doi.org/10.1099/jmmcr.0.000061.
19. Skov M, Koch C, Reimert CM, et al. Diagnosis of allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis. Allergy. 2000;55:50–8.
20. Thronicke A, Heger N, Antweiler E, et al. Allergic bronchopulmonary aspergillosis is associated with pet ownership in cystic fibrosis. Pediatr Allergy Immunol. 2016;27:597–603.
21. Agatha D, Krishnan KU, Dillirani VA, et al. Invasive lung infection by Scedosporium apiospermum in an immunocompetent individual. Indian J Pathol Microbiol. 2014;57:635–7.
22. Baxter CG, Dunn G, Jones AM, et al. Novel immunologic classification of aspergillosis in adult cystic fibrosis. J Allergy Clin Immunol. 2013;132(560–6):e10.
23. Caston JJ, Linares MJ, Rivero A, et al. Clinical differences between invasive pulmonary infection by Scedosporium apiospermum and invasive pulmonary aspergillosis. Mycoses. 2011;54:e468–73.
24. Chotirmall SH. Candida albicans in cystic fibrosis: “Opening statements presented, let the trial begin”. Pediatr Pulmonol. 2016;51:445–6.
25. Chotirmall SH, Greene CM, McElvaney NG. Candida species in cystic fibrosis: a road less travelled. Med Mycol. 2010;48(Suppl 1):S114–24.
26. Gileles-Hillel A, Shoseyov D, Polacheck I, et al. Association of chronic Candida albicans respiratory infection with a more severe lung disease in patients with cystic fibrosis. Pediatr Pulmonol. 2015;50:1082–9.
27. Haase G, Skopnik H, Kusenbach G. Exophiala dermatitidis infection in cystic fibrosis. Lancet. 1990;336:188–9.
28. Holle J, Leichsenring M, Meissner PE. Nebulized voriconazole in infections with Scedosporium apiospermum–case report and review of the literature. J Cyst Fibros. 2014;13:400–2.
29. Kosmidis C, Denning DW. The clinical spectrum of pulmonary aspergillosis. Thorax. 2015;70:270–7.
30. Kusenbach G, Skopnik H, Haase G, et al. Exophiala dermatitidis pneumonia in cystic fibrosis. Eur J Pediatr. 1992;151:344–6.
31. Shoseyov D, Brownlee KG, Conway SP, et al. Aspergillus bronchitis in cystic fibrosis. Chest. 2006;130:222–6.
32. Chotirmall SH, O’Donoghue E, Bennett K, et al. Sputum Candida albicans presages FEV(1) decline and hospital-treated exacerbations in cystic fibrosis. Chest. 2010;138:1186–95.
33. Hector A, Kirn T, Ralhan A, et al. Microbial colonization and lung function in adolescents with cystic fibrosis. J Cyst Fibros. 2016;15:340–9.
34. Muthig M, Hebestreit A, Ziegler U, et al. Persistence of Candida species in the respiratory tract of cystic fibrosis patients. Med Mycol. 2010;48:56–63.
35. Reihill JA, Moore JE, Elborn JS, et al. Effect of Aspergillus fumigatus and Candida albicans on pro-inflammatory response in cystic fibrosis epithelium. J Cyst Fibros. 2011;10:401–6.
36. Bonvillain RW, Valentine VG, Lombard G, et al. Post-operative infections in cystic fibrosis and non-cystic fibrosis patients after lung transplantation. J Heart Lung Transplant. 2007;26:890–7.
37. Hong G, White M, Lechtzin N, et al. Fatal disseminated Rasamsonia infection in cystic fibrosis post-lung transplantation. J Cyst Fibros. 2017;16:e3–7.
38. Iversen M, Burton CM, Vand S, et al. Aspergillus infection in lung transplant patients: incidence and prognosis. Eur J Clin Microbiol Infect Dis. 2007;26:879–86.
39. Johnson LS, Shields RK, Clancy CJ. Epidemiology, clinical manifestations, and outcomes of Scedosporium infections among solid organ transplant recipients. Transpl Infect Dis. 2014;16:578–87.
40. Luong ML, Chaparro C, Stephenson A, et al. Pretransplant Aspergillus colonization of cystic fibrosis patients and the incidence of post-lung transplant invasive aspergillosis. Transplantation. 2014;97:351–7.
41. Rolfe NE, Haddad TJ, Wills TS. Management of Scedosporium apiospermum in a pre- and post-lung transplant patient with cystic fibrosis. Med Mycol Case Rep. 2013;2:37–9.
42. Sole A, Morant P, Salavert M, et al. Aspergillus infections in lung transplant recipients: risk factors and outcome. Clin Microbiol Infect. 2005;11:359–65.
43. Cuenca-Estrella M, Alastruey-Izquierdo A, Alcazar-Fuoli L, et al. In vitro activities of 35 double combinations of antifungal agents against Scedosporium apiospermum and Scedosporium prolificans. Antimicrob Agents Chemother. 2008;52:1136–9.
44. Gilgado F, Serena C, Cano J, et al. Antifungal susceptibilities of the species of the Pseudallescheria boydii complex. Antimicrob Agents Chemother. 2006;50:4211–3.
45. Houbraken J, Giraud S, Meijer M, et al. Taxonomy and antifungal susceptibility of clinically important Rasamsonia species. J Clin Microbiol. 2013;51:22–30.
46. Kirchhoff L, Olsowski M, Zilmans K, et al. Biofilm formation of the black yeast-like fungus Exophiala dermatitidis and its susceptibility to antiinfective agents. Sci Rep. 2017;7:42886.
47. Lackner M, de Hoog GS, Verweij PE, et al. Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species. Antimicrob Agents Chemother. 2012;56:2635–42.
48. Mortensen KL, Johansen HK, Fuursted K, et al. A prospective survey of Aspergillus spp. in respiratory tract samples: prevalence, clinical impact and antifungal susceptibility. Eur J Clin Microbiol Infect Dis. 2011;30:1355–63.
49. Packeu A, Lebecque P, Rodriguez-Villalobos H, et al. Molecular typing and antifungal susceptibility of Exophiala isolates from patients with cystic fibrosis. J Med Microbiol. 2012;61:1226–33.
50. Rodriguez MM, Calvo E, Serena C, et al. Effects of double and triple combinations of antifungal drugs in a murine model of disseminated infection by Scedosporium prolificans. Antimicrob Agents Chemother. 2009;53:2153–5.
51. Sedlacek L, Graf B, Schwarz C, et al. Prevalence of Scedosporium species and Lomentospora prolificans in patients with cystic fibrosis in a multicenter trial by use of a selective medium. J Cyst Fibros. 2015;14:237–41.
52. Valenza G, Tappe D, Turnwald D, et al. Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis. J Cyst Fibros. 2008;7:123–7.
53. Padoan R, Poli P, Colombrita D, et al. Acute Scedosporium apiospermum Endobronchial Infection in Cystic Fibrosis. Pediatr Infect Dis J. 2016;35:701–2.
54. Roehmel JF, Tintelnot K, Bernhardt A, et al. Arxula adeninivorans causing invasive pulmonary mycosis and fungaemia in cystic fibrosis. Lancet. 2015;385:1476.
55. Liu JC, Modha DE, Gaillard EA. What is the clinical significance of filamentous fungi positive sputum cultures in patients with cystic fibrosis? J Cyst Fibros. 2013;12:187–93.
56. Middleton PG, Chen SC, Meyer W. Fungal infections and treatment in cystic fibrosis. Curr Opin Pulm Med. 2013;19:670–5.
57. Muller FM, Seidler M. Characteristics of pathogenic fungi and antifungal therapy in cystic fibrosis. Expert Rev Anti Infect Ther. 2010;8:957–64.
58. Chotirmall SH, McElvaney NG. Fungi in the cystic fibrosis lung: bystanders or pathogens? Int J Biochem Cell Biol. 2014;52:161–73.
59. Platts-Mills TA, Schuyler AJ, Erwin EA, et al. IgE in the diagnosis and treatment of allergic disease. J Allergy Clin Immunol. 2016;137:1662–70.
60. Fukutomi Y, Tanimoto H, Yasueda H, et al. Serological diagnosis of allergic bronchopulmonary mycosis: progress and challenges. Allergol Int. 2016;65:30–6.
61. Richardson MD, Page ID. Aspergillus serology: have we arrived yet? Med Mycol. 2017;55:48–55.
62. Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol. 2010;28:445–89.
63. Chaudhry A, Rudra D, Treuting P, et al. CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner. Science. 2009;326:986–91.
64. Koch MA, Tucker-Heard G, Perdue NR, et al. The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat Immunol. 2009;10:595–602.
65. Levine AG, Medoza A, Hemmers S, et al. Stability and function of regulatory T cells expressing the transcription factor T-bet. Nature. 2017;546:421–5.
66. Sefik E, Geva-Zatorsky N, Oh S, et al. MUCOSAL IMMUNOLOGY. Individual intestinal symbionts induce a distinct population of RORgamma(+) regulatory T cells. Science. 2015;349:993–7.
67. Zheng Y, Chaudhry A, Kas A, et al. Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control T(H)2 responses. Nature. 2009;458:351–6.
68. Bacher P, Scheffold A. Flow-cytometric analysis of rare antigen-specific T cells. Cytometry A. 2013;83:692–701.
69. Bacher P, Scheffold A. New technologies for monitoring human antigen-specific T cells and regulatory T cells by flow-cytometry. Curr Opin Pharmacol. 2015;23:17–24.
70. Davis MM, Altman JD, Newell EW. Interrogating the repertoire: broadening the scope of peptide-MHC multimer analysis. Nat Rev Immunol. 2011;11:551–8.
71. Bacher P, Kniemeyer O, Teutschbein J, et al. Identification of immunogenic antigens from Aspergillus fumigatus by direct multiparameter characterization of specific conventional and regulatory CD4+ T cells. J Immunol. 2014;193:3332–43.
72. Bacher P, Kniemeyer O, Schonbrunn A, et al. Antigen-specific expansion of human regulatory T cells as a major tolerance mechanism against mucosal fungi. Mucosal Immunol. 2014;7:916–28.
73. Bacher P, Schink C, Teutschbein J, et al. Antigen-reactive T cell enrichment for direct, high-resolution analysis of the human naive and memory Th cell repertoire. J Immunol. 2013;190:3967–76.
74. Bacher P, Steinbach A, Kniemeyer O, et al. Fungus-specific CD4(+) T cells for rapid identification of invasive pulmonary mold infection. Am J Respir Crit Care Med. 2015;191:348–52.
75. Bozza S, Clavaud C, Giovannini G, et al. Immune sensing of Aspergillus fumigatus proteins, glycolipids, and polysaccharides and the impact on Th immunity and vaccination. J Immunol. 2009;183:2407–14.
76. Chai LY, van de Veerdonk F, Marijnissen RJ, et al. Anti-Aspergillus human host defence relies on type 1 T helper (Th1), rather than type 17 T helper (Th17), cellular immunity. Immunology. 2010;130:46–54.
77. Chaudhary N, Staab JF, Marr KA. Healthy human T-cell responses to Aspergillus fumigatus antigens. PLoS ONE. 2010;5:e9036.
78. Hebart H, Bollinger C, Fisch P, et al. Analysis of T-cell responses to Aspergillus fumigatus antigens in healthy individuals and patients with hematologic malignancies. Blood. 2002;100:4521–8.
79. Jolink H, de Boer R, Hombrink P, et al. Pulmonary immune responses against Aspergillus fumigatus are characterized by high frequencies of IL-17 producing T-cells. J Infect. 2017;74:81–8.
80. Jolink H, de Boer R, Willems LN, et al. T helper 2 response in allergic bronchopulmonary aspergillosis is not driven by specific Aspergillus antigens. Allergy. 2015;70:1336–9.
81. Jolink H, Hagedoorn RS, Lagendijk EL, et al. Induction of A. fumigatus-specific CD4-positive T cells in patients recovering from invasive aspergillosis. Haematologica. 2014;99:1255–63.
82. Jolink H, Meijssen IC, Hagedoorn RS, et al. Characterization of the T-cell-mediated immune response against the Aspergillus fumigatus proteins Crf1 and catalase 1 in healthy individuals. J Infect Dis. 2013;208:847–56.
83. Knutsen AP, Mueller KR, Levine AD, et al. Asp f I CD4+ TH2-like T-cell lines in allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol. 1994;94:215–21.
84. Kreindler JL, Steele C, Nguyen N, et al. Vitamin D3 attenuates Th2 responses to Aspergillus fumigatus mounted by CD4+ T cells from cystic fibrosis patients with allergic bronchopulmonary aspergillosis. J Clin Invest. 2010;120:3242–54.
85. Potenza L, Vallerini D, Barozzi P, et al. Characterization of specific immune responses to different Aspergillus antigens during the course of invasive Aspergillosis in hematologic patients. PLoS ONE. 2013;8:e74326.
86. Potenza L, Vallerini D, Barozzi P, et al. Mucorales-specific T cells emerge in the course of invasive mucormycosis and may be used as a surrogate diagnostic marker in high-risk patients. Blood. 2011;118:5416–9.
87. Stuehler C, Nowakowska J, Bernardini C, et al. Multispecific Aspergillus T cells selected by CD137 or CD154 induce protective immune responses against the most relevant mold infections. J Infect Dis. 2015;211:1251–61.
88. Vallerini D, Forghieri F, Lagreca I, et al. Detection of Fusarium-specific T cells in hematologic patients with invasive fusariosis. J Infect. 2017;74:314–8.
89. Day CL, Seth NP, Lucas M, et al. Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. J Clin Invest. 2003;112:831–42.
90. Su LF, Kidd BA, Han A, et al. Virus-specific CD4(+) memory-phenotype T cells are abundant in unexposed adults. Immunity. 2013;38:373–83.
91. Stuehler C, Khanna N, Bozza S, et al. Cross-protective TH1 immunity against Aspergillus fumigatus and Candida albicans. Blood. 2011;117:5881–91.
92. Kwok WW, Tan V, Gillette L, et al. Frequency of epitope-specific naive CD4(+) T cells correlates with immunodominance in the human memory repertoire. J Immunol. 2012;188:2537–44.
93. Schoenbrunn A, Frentsch M, Kohler S, et al. A converse 4-1BB and CD40 ligand expression pattern delineates activated regulatory T cells (Treg) and conventional T cells enabling direct isolation of alloantigen-reactive natural Foxp3 + Treg. J Immunol. 2012;189:5985–94.
94. Green BJ, Sercombe JK, Tovey ER. Fungal fragments and undocumented conidia function as new aeroallergen sources. J Allergy Clin Immunol. 2005;115:1043–8.
95. Tovey ER, Green BJ. Measuring environmental fungal exposure. Med Mycol. 2005;43(Suppl 1):S67–70.
96. Huffnagle GB, Noverr MC. The emerging world of the fungal microbiome. Trends Microbiol. 2013;21:334–41.
97. Cutler JE, Deepe GS Jr, Klein BS. Advances in combating fungal diseases: vaccines on the threshold. Nat Rev Microbiol. 2007;5:13–28.
98. Brown GD, Denning DW, Gow NA, et al. Hidden killers: human fungal infections. Sci Transl Med. 2012;4:165rv13.
99. Marr KA. Fungal infections in hematopoietic stem cell transplant recipients. Med Mycol. 2008;46:293–302.
100. Lionakis MS, Iliev ID, Hohl TM. Immunity against fungi. JCI Insight. 2017;2.
101. Acosta-Rodriguez EV, Rivino L, Geginat J, et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol. 2007;8:639–46.
102. Becattini S, Latorre D, Mele F, et al. T cell immunity. Functional heterogeneity of human memory CD4(+) T cell clones primed by pathogens or vaccines. Science. 2015;347:400–6.
103. Bacher P, Heinrich F, Stervbo U, et al. Regulatory T cell specificity directs tolerance versus allergy against aeroantigens in humans. Cell. 2016;167(1067–78):e16.
104. Borghi M, Renga G, Puccetti M, et al. Antifungal Th Immunity: growing up in Family. Front Immunol. 2014;5:506.
105. Chen K, Kolls JK. T cell-mediated host immune defenses in the lung. Annu Rev Immunol. 2013;31:605–33.
106. Eyerich K, Foerster S, Rombold S, et al. Patients with chronic mucocutaneous candidiasis exhibit reduced production of Th17-associated cytokines IL-17 and IL-22. J Invest Dermatol. 2008;128:2640–5.
107. Ma CS, Chew GY, Simpson N, et al. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J Exp Med. 2008;205:1551–7.
108. Milner JD, Brenchley JM, Laurence A, et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature. 2008;452:773–6.
109. Okada S, Markle JG, Deenick EK, et al. IMMUNODEFICIENCIES. Impairment of immunity to Candida and Mycobacterium in humans with bi-allelic RORC mutations. Science. 2015;349:606–13.
110. Puel A, Cypowyj S, Bustamante J, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science. 2011;332:65–8.
111. Vinh DC. Insights into human antifungal immunity from primary immunodeficiencies. Lancet Infect Dis. 2011;11:780–92.
112. de Beaucoudrey L, Samarina A, Bustamante J, et al. Revisiting human IL-12Rbeta1 deficiency: a survey of 141 patients from 30 countries. Medicine (Baltimore). 2010;89:381–402.
113. Moraes-Vasconcelos D, Grumach AS, Yamaguti A, et al. Paracoccidioides brasiliensis disseminated disease in a patient with inherited deficiency in the beta1 subunit of the interleukin (IL)-12/IL-23 receptor. Clin Infect Dis. 2005;41:e31–7.
114. Vinh DC, Masannat F, Dzioba RB, et al. Refractory disseminated coccidioidomycosis and mycobacteriosis in interferon-gamma receptor 1 deficiency. Clin Infect Dis. 2009;49:e62–5.
115. Vinh DC, Schwartz B, Hsu AP, et al. Interleukin-12 receptor beta1 deficiency predisposing to disseminated Coccidioidomycosis. Clin Infect Dis. 2011;52:e99–102.
116. Zerbe CS, Holland SM. Disseminated histoplasmosis in persons with interferon-gamma receptor 1 deficiency. Clin Infect Dis. 2005;41:e38–41.
117. Browne SK, Burbelo PD, Chetchotisakd P, et al. Adult-onset immunodeficiency in Thailand and Taiwan. N Engl J Med. 2012;367:725–34.
118. Lanternier F, Cypowyj S, Picard C, et al. Primary immunodeficiencies underlying fungal infections. Curr Opin Pediatr. 2013;25:736–47.
119. Rosen LB, Freeman AF, Yang LM, et al. Anti-GM-CSF autoantibodies in patients with cryptococcal meningitis. J Immunol. 2013;190:3959–66.
120. Bedke T, Iannitti RG, De Luca A, et al. Distinct and complementary roles for Aspergillus fumigatus-specific Tr1 and Foxp3 + regulatory T cells in humans and mice. Immunol Cell Biol. 2014;92:659–70.
121. Montagnoli C, Fallarino F, Gaziano R, et al. Immunity and tolerance to Aspergillus involve functionally distinct regulatory T cells and tryptophan catabolism. J Immunol. 2006;176:1712–23.
122. Iannitti RG, Carvalho A, Cunha C, et al. Th17/Treg imbalance in murine cystic fibrosis is linked to indoleamine 2,3-dioxygenase deficiency but corrected by kynurenines. Am J Respir Crit Care Med. 2013;187:609–20.
123. Sewell AK. Why must T cells be cross-reactive? Nat Rev Immunol. 2012;12:669–77.
124. Su LF, Han A, McGuire HM, et al. The promised land of human immunology. Cold Spring Harb Symp Quant Biol. 2013;78:203–13.
125. Potenza L, Vallerini D, Barozzi P, et al. Mucorales-specific T cells in patients with hematologic malignancies. PLoS ONE. 2016;11:e0149108.
126. el-Dahr JM, Fink R, Selden R, et al. Development of immune responses to Aspergillus at an early age in children with cystic fibrosis. Am J Respir Crit Care Med. 1994;150:1513–8.
127. Hutcheson PS, Rejent AJ, Slavin RG. Variability in parameters of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. J Allergy Clin Immunol. 1991;88:390–4.
128. Nicolai T, Arleth S, Spaeth A, et al. Correlation of IgE antibody titer to Aspergillus fumigatus with decreased lung function in cystic fibrosis. Pediatr Pulmonol. 1990;8:12–5.
129. Stevens DA, Moss RB, Kurup VP, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis–state of the art: cystic fibrosis foundation consensus conference. Clin Infect Dis. 2003;37(Suppl 3):S225–64.
130. Zeaske R, Bruns WT, Fink JN, et al. Immune responses to Aspergillus in cystic fibrosis. J Allergy Clin Immunol. 1988;82:73–7.
131. Becker KL, Gresnigt MS, Smeekens SP, et al. Pattern recognition pathways leading to a Th2 cytokine bias in allergic bronchopulmonary aspergillosis patients. Clin Exp Allergy. 2015;45:423–37.
132. Knutsen AP, Slavin RG. Allergic bronchopulmonary aspergillosis in asthma and cystic fibrosis. Clin Dev Immunol. 2011;2011:843763.
133. King J, Brunel SF, Warris A. Aspergillus infections in cystic fibrosis. J Infect. 2016;72(Suppl):S50–5.
134. Allen JE, Sutherland TE, Ruckerl D. IL-17 and neutrophils: unexpected players in the type 2 immune response. Curr Opin Immunol. 2015;34:99–106.
135. Weaver CT, Elson CO, Fouser LA, et al. The Th17 pathway and inflammatory diseases of the intestines, lungs, and skin. Annu Rev Pathol. 2013;8:477–512.
136. Zelante T, Bozza S, De Luca A, et al. Th17 cells in the setting of Aspergillus infection and pathology. Med Mycol. 2009;47(Suppl 1):S162–9.